Oral tranexamic acid
Phase 3
Oral tranexamic acid is one of 47 therapeutic programs targeting Coronary Artery Disease. It is currently in Phase 3.
2
Indications
2
Total Trials
2
Active Trials
46
Competitors
Pipeline
Status by Indication[2][1]
Competition
Competitive Landscape
117 competitors in Coronary Artery Disease
#DrugCompanyPhaseTrials
1Bayer Aspirin
BayerApproved
Brilinta
AstraZenecaApproved
Crestor
AstraZenecaApproved
Farxiga
AstraZenecaApproved
Ozempic
Novo NordiskApproved
Niacor
AbbVieApproved
Effient
CCosette Pharmaceuticals, Inc.
Approved
Glucophage
EMD SeronoApproved
Cardizem
BBausch Health Americas, Inc.
Approved
Ranexa
MMenarini International Operations Luxembourg SA
Approved
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]Open Targets Platform — Drug–disease associations for Oral tranexamic acid. EMBL-EBI & Wellcome Sanger Institute.
- [3]
Details
Drug Info
Quick Facts
- Highest Phase
- Phase 3[1]
- Company
- CClinique Saint-Luc